Startup, Novella, debuts line of whole-cell cultivated berry phytonutrients
The startup uses a precision-controlled-environment technology that allows them to cultivate intact-cell berry compounds outside of the plant.
Image courtesy of Novella Ltd.
Novella Ltd., a nutri-tech startup based in Modiin, Israel, has unveiled prototypes of its new line of berry-derived bioactives. The startup uses a precision-controlled-environment technology that allows them to cultivate intact-cell berry compounds outside of the plant. According to the company’s press release, the platform will ease bottlenecks in the supply chain of highly in-demand berry ingredients, as well as reduce carbon emissions and plant waste.
To accelerate the cultivation the whole-berry fruit cells from five varieties, Novella opened a new facility that will operate as its operational headquarters and pilot plant. Each variety is designed to meet distinct supplement market demands, according to the company’s press release.
“Berries cultivated solely for supplements on average require about 2,000 acres to yield just one ton of polyphenolic compounds,” explained Itay Dana, co-founder and chief business development officer of Novella, in a press release. “We have condensed that vast tract of agriculture into a 10K liter bioreactor that produces the same quantity of pure, high-value ingredients. This frees up valuable land for cultivating food crops and provides a host of other economic and environmental benefits, beginning with the complete elimination of waste. Our method requires minimal land, energy, and water usage and exerts a minimal carbon footprint. We can produce high-quality ingredients at affordable prices, independently of climate fluctuations, logistical challenges, or social and political constraints.”
Novella explains that instead of extraction, the company screens the plant’s tissues to pinpoint areas of the highest concentration of compounds, and then the selected cells are grown in a closed, controlled system that stimulates natural propagation. Cells are then transformed into a nutritious and bioaccessible powder without the need for solvents. By keeping the cultivation at the cellular level, says Novella, the company is able to maintain the berry’s natural complex of phytonutrients, including vitamins, minerals, and polyphenols, including anthocyanins.
“We perform a one-time selection procedure, taking tissue from the skin and flesh of the berries while the fruit is in it most potent stage,” said chief technology officer, Moshe Flaishman, PhD. According to Flaishman, the company can also produce specific berry-derived ingredients by request.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
